Jim Cramer has highlighted Johnson & Johnson's stock as potentially undervalued following a recent FDA approval. According to NS3.AI, the company's shares have dropped over 6% in the past month, currently trading at $227. Cramer noted that the approval of Icotyde has been overshadowed by broader healthcare sector noise, suggesting that the current weakness in the stock might present a buying opportunity for investors.